Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
6.30
-0.16 (-2.48%)
At close: Apr 28, 2026, 4:00 PM EDT
6.31
+0.01 (0.16%)
After-hours: Apr 28, 2026, 4:43 PM EDT
Taysha Gene Therapies Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Taysha Gene Therapies stock have an average target of 11.11, with a low estimate of 7.00 and a high estimate of 17. The average target predicts an increase of 76.35% from the current stock price of 6.30.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Taysha Gene Therapies stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $14 → $17 | Strong Buy | Maintains | $14 → $17 | +169.84% | Apr 6, 2026 |
| Needham | Needham | Strong Buy Maintains $10 → $12 | Strong Buy | Maintains | $10 → $12 | +90.48% | Mar 19, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 | Strong Buy | Maintains | $12 | +90.48% | Mar 19, 2026 |
| Needham | Needham | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +58.73% | Mar 3, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 | Strong Buy | Maintains | $12 | +90.48% | Jan 6, 2026 |
Financial Forecast
Revenue This Year
3.51M
from 9.77M
Decreased by -64.06%
Revenue Next Year
43.99M
from 3.51M
Increased by 1,152.42%
EPS This Year
-0.41
from -0.34
EPS Next Year
-0.45
from -0.41
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 15.8M | 121.5M | ||||||
| Avg | 3.5M | 44.0M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 61.2% | 3,360.4% | ||||||
| Avg | -64.1% | 1,152.4% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.40 | -0.13 | ||||||
| Avg | -0.41 | -0.45 | ||||||
| Low | -0.47 | -0.61 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.